NF1 and schwannoma: Inhibition of these pathways, together with inhibition of the LIMKs by T56-LIMKi or other inhibitors, may also synergistically reverse the malignant phenotype of neurofibromin-depleted cells, including NF1−/− schwannoma in neurofibromatosis, and of other cancer cells.